Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Newly formed Durata buys Vicuron from Pfizer

Executive Summary

Five venture firms--Aisling Capital, Canaan Partners, Domain Associates, New Leaf Venture Partners, and Sofinnova Ventures--have created Durata Therapeutics to acquire Pfizer's absorbed Vicuron Pharmaceuticals subsidiary. Durata issued an undisclosed amount of stock to pay for the transaction.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies